Department of Neuroscience, Reproductive Sciences and Dentistry, "Federico II" University, Naples, Italy.
Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy.
Pharmacol Res. 2023 Jan;187:106557. doi: 10.1016/j.phrs.2022.106557. Epub 2022 Nov 17.
An empathetic approach may be particularly useful in patients with therapy-resistant hypertension (TRH), defined as the failure to achieve target blood pressure (BP) despite a maximal doses of 3 antihypertensive drugs including a diuretic. However, the effects of therapeutic concordance have not been determined in hypertensive patients.
We designed a study to explore the impact of therapeutic concordance in patients with TRH, who were included in an intervention arm based on a protocol in which trained personnel periodically verified the pharmacological regimen of these patients.
From a cohort of 5331 hypertensive patients followed-up for 77.64 ± 34.44 months, 886 subjects were found to have TRH; of these, 322 had apparent TRH (aTRH: uncontrolled office BP but optimal home BP) and 285 refused to participate in a second follow-up study, yielding a population of 279 patients with true TRH (tTRH). These tTRH patients were followed according to the therapeutic concordance protocol for 91.91 ± 54.7 months, revealing that 210 patients (75.27%) remained with uncontrolled BP (uncontrolled tTRH, Group I) while 69 patients (24.73%) reached an optimal BP control (average BP <140/90 mmHg in at least 50% of follow-up visits, Group II). Strikingly, at the end of the second follow-up, the percentage of patients displaying a decline in kidney function was significantly smaller in Group II than in Group I (8.5% vs 23.4%, p < 0.012).
Taken together, our findings indicate for the first time that therapeutic concordance significantly improves the outcome of antihypertensive treatment in a population of patients with TRH.
在治疗抵抗性高血压(TRH)患者中,共情方法可能特别有用,TRH 定义为尽管使用了包括利尿剂在内的 3 种降压药物的最大剂量,但仍无法达到目标血压(BP)。然而,在高血压患者中,治疗一致性的效果尚未确定。
我们设计了一项研究,以探讨治疗一致性对 TRH 患者的影响,这些患者根据一项方案被纳入干预组,该方案中,经过培训的人员定期检查这些患者的药物治疗方案。
在一项随访了 77.64±34.44 个月的 5331 例高血压患者队列中,发现 886 例患者患有 TRH;其中,322 例为明显 TRH(aTRH:诊室血压不受控制,但家庭血压最佳),285 例拒绝参加第二次随访研究,因此,真正的 TRH 患者(tTRH)有 279 例。根据治疗一致性方案对这些 tTRH 患者进行了 91.91±54.7 个月的随访,结果显示,210 例患者(75.27%)仍存在未控制的血压(未控制的 tTRH,组 I),而 69 例患者(24.73%)达到了最佳血压控制(至少 50%的随访访视中平均 BP<140/90mmHg,组 II)。引人注目的是,在第二次随访结束时,与组 I 相比,组 II 中肾功能下降的患者比例明显更小(8.5%比 23.4%,p<0.012)。
总之,我们的研究结果首次表明,治疗一致性可显著改善 TRH 患者人群的降压治疗效果。